Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
FCEL....MADCOW here is latest Short pos. that I see.
Shares Short (as of 12-Feb-07)3: 8.54M
Short Ratio (as of 12-Feb-07)3: 8
Short % of Float (as of 12-Feb-07)3: 15.50%
Shares Short (prior month)3: 7.62M
INSM 1.03
INSM 1.04
PCU on fire again today
Anyone in GOOG.....its been beaten up to the point its starting to look juicy to me. Any thoughts?
INSM....I'm hoping we see 1.05 - 1.10 before close. Then after the bell we see what the company has to say.
INSM on the move agian today at HOD
INSM moving up again today
INSM moving up again today
Anyone watching DOW......I was going to add it to my long term portfolio yesterday but bought more AMTD. Supposedly there was a write up in the past few weeks about DOW getting taken out at around $60, anyone else here anything?
I was thinking the same thing....LOL
INSM....Your right just looked it up they come out tomorrow.......
RICHMOND, Va., Mar 10, 2007 (BUSINESS WIRE) -- Insmed today announced that it will release its 2006 fourth quarter and year end financial results after market close on Thursday, March 15, 2007.
Management will host an investment community conference call beginning at 4:30 p.m. Eastern Time, on Thursday March 15, to discuss the financial results, provide a business update and answer questions.
Individuals interested in listening to the live conference call may do so by dialing (877) 407-0782 toll free within the U.S. and Canada, or (201) 689-8567 for international callers.
A telephone replay will be available approximately two hours after the call for two weeks by dialing (877) 660-6853 from the U.S., or (201) 612-7415 for international callers. The account code is 286; the conference number is 234775.
Individuals interested in listening to the conference call via the Internet may do so by visiting www.insmed.com. A replay will be available on the Company's Web site for two weeks.
About Insmed
Insmed Inc. is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com
SOURCE: Insmed Incorporated
PCU looking nice and strong here
INSM at HOD $1
INSM at HOD $1
INSM at HOD $1
AMTD holding up today.....got back in yesterday
INSM bid picking up a little bit right now
KRY....Any of you play this one today?
INSM getting gobbled up right now......97
What is going on with INSM again?
What got into INSM again?
INSM getting slapped right back down from around a buck
INSM....Looks like some buying is coming into the close.
In Lazard's question he asking the obvious question as to why do you keep that many people on,his exact term I believe was "froth", erespective of trials or not it just seemed to him they were retaining a lot of people on that side and that is when he then asked how many people in Italy were actually on the drug. All I'm saying is maybe INSM expects to get more people on the drug in Italy and that is why they didn't cut production substantially.....Maybe I'm just trying to find a silver lining.....All Just my humble opinions of course.
ONE Question.......having listened to some of the Conference call before a meeting something stuck in my head..
The guy from LAZARD asked if you have no market for the drug then why only cut 34% of your work force? And what would the break up be? The answer was the important part to me the company stated that roughly 100 people would be left with 80% in production and 20% for other purposes if im not mistaken. This leads me to my own question......If you dont have a market for the drug why would you keep 80 on the production side unless you have some kind of data that tells you your going to need to keep up the manufacturing aspect? Like I said I had to cut out early so if any of you could enlighten me it would be much appreciated.
INSM...Listening to the call right now.
INSM.....may not be as bad as first thought....here is something from another thread.....
IPLEX can still be given to shortstature patients who specifically request IPLEX at 40% royalty. Yes the royalty is high, but it's not exactly off the market.
IPLEX can be given to ALS, and other non-TRCA indications at 4% royalty.
This is from the TRCA conference call Q&A
INSM..Im wait and see right now also. Own a lot of shares but at a low cost basis. Going to listen to the call today and see what happens.
Looks like they gave up to much unless they have some data from the Phase II trials for other applications in there back pockets. If not looks like they would have been better off throwing themselves at the mercy of the court. What gets me thinking is that DNA is offering to pick up a lot of the tab for future applications of the drug and trials. All MHO though.
You think INSM will be halted until after their conference call?
Take a look at GNTA today had some news.
KRY is also moving
RIO, INSM, FTEK, PCU, all looking strong, nice to see green. Of the 29 stocks I am tracking 28 are green right now.
It's up about $1 in pre market but that has more to do with the general market then anything else IMHO.
What is going on with MO?????? I thought it was a defensive stock. Bought more yesterday should have held off another day. Can't believe it is down going into the split later this month.
INSM hanging in there. FYI found this note by Lazard
Insmed "buy"
Monday, February 19, 2007 4:07:30 AM ET
Lazard Capital Markets
NEW YORK, February 19 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on Insmed Inc (ticker: INSM). The target price is set to $3.
In a research note published on February 16, the analysts mention that as a result of stipulation submitted to the court by Insmed and Tercica, the preliminary injunction hearing has been delayed. The reasons for the delay in the hearing and when it would be scheduled appear uncertain, the analysts say.
Recommend this article to a friend
INSM.NAS | detailed quote - chart - all headlines - add to watchlist
INSM hanging in there. FYI found this note by Lazard
Insmed "buy"
Monday, February 19, 2007 4:07:30 AM ET
Lazard Capital Markets
NEW YORK, February 19 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on Insmed Inc (ticker: INSM). The target price is set to $3.
In a research note published on February 16, the analysts mention that as a result of stipulation submitted to the court by Insmed and Tercica, the preliminary injunction hearing has been delayed. The reasons for the delay in the hearing and when it would be scheduled appear uncertain, the analysts say.
Recommend this article to a friend
INSM.NAS | detailed quote - chart - all headlines - add to watchlist
INSM hanging in there. FYI found this note by Lazard
Insmed "buy"
Monday, February 19, 2007 4:07:30 AM ET
Lazard Capital Markets
NEW YORK, February 19 (newratings.com) - Analysts at Lazard Capital maintain their "buy" rating on Insmed Inc (ticker: INSM). The target price is set to $3.
In a research note published on February 16, the analysts mention that as a result of stipulation submitted to the court by Insmed and Tercica, the preliminary injunction hearing has been delayed. The reasons for the delay in the hearing and when it would be scheduled appear uncertain, the analysts say.
Recommend this article to a friend
INSM.NAS | detailed quote - chart - all headlines - add to watchlist
Welcome the water is fine...LOL. In granting two stays the speculation is rampant as to what might happen. From all accounts INSM might have many more applications for its drug then TRCA so I could see the speculation that DNA and TRCA would want to cut some kind of deal.....JMHO of course.